- CDC News
- Adult Immunization
- Hepatology
- Rare Disorders
- Pediatric Immunization
- Weight Management
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Kidney Disease
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Orthopedics
- Obesity Medicine
- Rheumatology
- Technology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Diabetes Review: The 2 New Insulins on the Block
Got a minute? Check out this concise review of the facts about long-acting insulin formulations Toujeo and Tresiba.
Two new long-acting insulin products were recently approved by the FDA. Toujeo (insulin glargine 300 units/mL) and Tresiba (insulin degludec 100 units/mL or 200 units/mL).In clinical trials both were found comparable to Lantus (insulin glargine) and Levemir (insulin detemir [rDNA origin] injection), with regard to lowering A1c; both may also be associated with lower rates of nocturnal hypoglycemia.Click through the 8 slides above for a quick review of more features of both.Sources:Toujeo [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC.; 2015.Tresiba [package insert]. Bagsvaerd, Denmark: Novo Nordisk; 2015.Cost information available from: REDBOOK Online. Accessed Feb 1, 2016.
